Using data from an open-label, single-arm Phase 2 trial on patients with Stage IV LUSC or NSCLC (NCT02417701), they found that LUSC with NRF2Mut or KEAP1Mut, but not KRAS/KEAP1 or NRF2 co-mutations, responded to this compound [151]. Here, KRAS is linked to non-small cell lung carcinoma.